These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29464559)

  • 21. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benzyloxynitrostyrene analogues - A novel class of selective and highly potent inhibitors of monoamine oxidase B.
    Van der Walt MM; Terre'Blanche G; Petzer JP; Petzer A
    Eur J Med Chem; 2017 Jan; 125():1193-1199. PubMed ID: 27855360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benextramine and derivatives as novel human monoamine oxidases inhibitors: an integrated approach.
    Di Paolo ML; Cozza G; Milelli A; Zonta F; Sarno S; Minniti E; Ursini F; Rosini M; Minarini A
    FEBS J; 2019 Dec; 286(24):4995-5015. PubMed ID: 31291696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
    Chen JJ; Wilkinson JR
    J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
    Yeon SK; Choi JW; Park JH; Lee YR; Kim HJ; Shin SJ; Jang BK; Kim S; Bahn YS; Han G; Lee YS; Pae AN; Park KD
    Bioorg Med Chem; 2018 Jan; 26(1):232-244. PubMed ID: 29198609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
    Bainbridge JL; Page RL; Ruscin JM
    Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure and mechanism of monoamine oxidase.
    Edmondson DE; Mattevi A; Binda C; Li M; Hubálek F
    Curr Med Chem; 2004 Aug; 11(15):1983-93. PubMed ID: 15279562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In silico identification of novel and selective monoamine oxidase B inhibitors.
    Yelekçi K; Büyüktürk B; Kayrak N
    J Neural Transm (Vienna); 2013 Jun; 120(6):853-8. PubMed ID: 23242744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diphenylene Iodonium Is a Noncovalent MAO Inhibitor: A Biochemical and Structural Analysis.
    Iacovino LG; Reis J; Mai A; Binda C; Mattevi A
    ChemMedChem; 2020 Aug; 15(15):1394-1397. PubMed ID: 32459875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interactions of monoamine oxidases with the antiepileptic drug zonisamide: specificity of inhibition and structure of the human monoamine oxidase B complex.
    Binda C; Aldeco M; Mattevi A; Edmondson DE
    J Med Chem; 2011 Feb; 54(3):909-12. PubMed ID: 21175212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding the Molecular Determinant of Reversible Human Monoamine Oxidase B Inhibitors Containing 2H-Chromen-2-One Core: Structure-Based and Ligand-Based Derived Three-Dimensional Quantitative Structure-Activity Relationships Predictive Models.
    Mladenović M; Patsilinakos A; Pirolli A; Sabatino M; Ragno R
    J Chem Inf Model; 2017 Apr; 57(4):787-814. PubMed ID: 28291352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular characteristics of a single and novel form of carp (Cyprinus carpio) monoamine oxidase.
    Sugimoto H; Taguchi YD; Shibata K; Kinemuchi H
    Comp Biochem Physiol B Biochem Mol Biol; 2010 Mar; 155(3):266-71. PubMed ID: 19932189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural properties of human monoamine oxidases A and B.
    Binda C; Mattevi A; Edmondson DE
    Int Rev Neurobiol; 2011; 100():1-11. PubMed ID: 21971000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoamine Oxidase B Inhibitors in Parkinson's Disease.
    Dezsi L; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(4):425-439. PubMed ID: 28124620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.
    Manzoor S; Hoda N
    Eur J Med Chem; 2020 Nov; 206():112787. PubMed ID: 32942081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-level expression of human liver monoamine oxidase B in Pichia pastoris.
    Newton-Vinson P; Hubalek F; Edmondson DE
    Protein Expr Purif; 2000 Nov; 20(2):334-45. PubMed ID: 11049757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of monoamine oxidase by benzoxathiolone analogues.
    Mostert S; Petzer A; Petzer JP
    Bioorg Med Chem Lett; 2016 Feb; 26(4):1200-4. PubMed ID: 26821818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional role of the "aromatic cage" in human monoamine oxidase B: structures and catalytic properties of Tyr435 mutant proteins.
    Li M; Binda C; Mattevi A; Edmondson DE
    Biochemistry; 2006 Apr; 45(15):4775-84. PubMed ID: 16605246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
    Weinreb O; Amit T; Riederer P; Youdim MB; Mandel SA
    Int Rev Neurobiol; 2011; 100():127-49. PubMed ID: 21971006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.